Results 21 to 30 of about 16,889 (275)
Tardive dyskinesia: Prevention and newer management strategies
Annals of Indian Psychiatry, 2020 Tardive dyskinesia (TD) is a condition where we have a limited understanding of the cause and of management. The delayed-onset movements can occur due to prolonged exposure to dopamine receptor-blocking agents (DRBAs).
Sreelakshmi Vaidyanathan +1 more
doaj +1 more source
No association of a set of candidate genes on haloperidol side effects [PDF]
, 2012 We previously investigated a sample of patients during an active phase of psychosis in the search for genetic predictors of haloperidol induced side effects.
Alessandro Serretti +31 more
core +1 more source
Relevance of animal models to human tardive dyskinesia
Behavioral and Brain Functions, 2012 Tardive dyskinesia remains an elusive and significant clinical entity that can possibly be understood via experimentation with animal models. We conducted a literature review on tardive dyskinesia modeling.
Blanchet Pierre J +3 more
doaj +1 more source
Investigation of PRKN Mutations in Levodopa-Induced Dyskinesia in Parkinson’s Disease Treatment
Biomedicines, 2023 Mitophagy is an important process that participates in mitochondrial quality control. Dysfunctions in this process can be caused by mutations in genes like PRKN and are associated with the development and progression of Parkinson’s Disease (PD). The most
Ana Gabrielle Bispo +7 more
doaj +1 more source
L-dopa: main drug induced dyskinesia
São Paulo Medical Journal, 2021 Introduction: 3,4-dihydroxy-L-phenylalanine (L-dopa) is the gold standard drug for the treatment of Parkinson’s disease (PD). This disease causes degeneration of dopaminergic cells, L-dopa supplies the lack of dopamine, being effective in its treatment.
Pedro Felisberto Nogueira Viana Farah +4 more
openaire +1 more source
Risperidone induced tardive dyskinesia
, 2021 Risperidone is an atypical antipsychotic drug which has been less likely to produce extrapyramidal symptoms. The aim of this case report is to illustrate that low dose risperidone may cause tardive dyskinesia.
Harichandran, Dhanya Thirookaran +2 more
core +1 more source
Preclinical models of levodopa-induced dyskinesia
, 2014 L -DOPA-induced dyskinesia (LID) represents one of the major limitations in the current pharmacotherapy of Parkinson's disease (PD) and affects the majority of PD patients.
Francardo, Veronica, +2 more
core +1 more source
Clinical Management of Drug Induced Dyskinesia in Parkinson's Disease: Why Current Approaches May Need to Be Changed to Optimise Quality of Life [PDF]
European Medical Journal, 2016 Parkinson’s disease is a complex, progressive neurodegenerative disorder associated with both motor and non-motor symptoms. Current treatment strategies mainly target the alleviation of motor symptoms through dopaminergic replacement therapy.
Jean-Francois Daneault +2 more
doaj
Neurology Perspectives, 2021 Resumen: La enfermedad de Parkinson (EP) es una enfermedad neurodegenerativa cuyo tratamiento sintomático más eficaz es la L-dopa, sin embargo, puede inducir discinesias (DIL).
J.C. Guzman +5 more
doaj +1 more source
Antipsychotic Drug Induced Tardive Dyskinesia
International Journal of Research in Pharmaceutical Sciences, 2020 A typical antipsychotics are at a lower risk of developing extra-pyramidal symptoms (EPS). But now, atypical antipsychotics are increasingly being associated with neurological side effects such as tardive dyskinesia, tardive dystonia, akinesia, parkinsonism, akathisia, bradykinesia, tremor etc.
null Gopika S Kumar +3 more
openaire +1 more source